Among their differences, it is worth mentioning that dasatinib, has the potential to target KIT and platelet-derived growth factor receptor (PDGFR) [50], as well as collagen receptor tyrosine kinases discoidin domain receptors 1 and 2 (DDR1, 2) [51], PI3K and ERK, potential targets for the treatment of RA [52, 53]. The gene discussed is DDR1; the disease is rheumatoid arthritis.